Maze Therapeutics (MAZE) Tops Q1 EPS by 13c

Maze Therapeutics (NASDAQ: MAZE) reported Q1 EPS of ($0.45), $0.13 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20 million.

For earnings history and earnings-related data on Maze Therapeutics (MAZE) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Trump says to rename Lake Ontario to Lake America
• TETRA Technologies (TTI) call put ratio 2 calls to 1 put with a focus on September 7 calls and March 7 puts